There is always shorting of the common when a convert is issued.
To the posters who don't like actions of the current management, I would only remind you that it was this management that took the risk and went all in on the Eagle Ford. Maybe you would look more kindly on management if you had recognized the potential of what they were doing and bought the stock in the 4s, like some of us did.
If I had accomplished what this management team has accomplished I would also want to be rewarded.
What did Soros do but wait until the production was skyrocketing and then make demands on management -- throwing his weight around.
When I look back at the moves this management has made in the last few years I don't see many missteps.
Gene therapy moving ahead at breakneck speed -- won't be that long until cures are here.
David Guyer, CEO of OPHT, just came on the board of AGTC this am.
OPHT, REGN telling you where the future lies.
AGTC now has alliance with Sigma-Aldrich to make AAV gene therapy more available to the research community.
People want to invest in disruptive technologies -- not primitive stopgaps.
Something like shale, maybe, but not exactly shale.
(Your question exceeds my level of knowledge of jurassic sedimentary formations)
REGN -- which has by far the best science — has made an important partnership with Avalanche and is now looking at CURES for retinal diseases. Therapies that treat retinal diseases as chronic are soon going to be yesterday's news. Look at a company like AGTC, which I believe has never even been mentioned here.
Retinal diseases are among the most genetically related of all human diseases. As REGN and AGTC have now indicated, gene replacement will be the real long-term CURE for retinal diseases. Everything else will be interim therapy if you are seeking a longer-term perspective.
The most knowledgeable venture capitalists are only interested in CURES at this point. So place your bets carefully of you might be backing a dying horse.
I started wondering about Livermore when he started to go on the REGN message board warning REGN shareholders that they were doomed. Seemed a bit much for a professional guy.
PVA is worth 20+ and that is all Soros cares about.
He is afraid management is getting more entrenched with recent moves.
If PVA is sold to another E+P , current management is out.
If PVA is sold to a major, the new owner might leave management in place and let them run a shale division with big financial support from the major.
Let Soros find a buyer who satisfies everyone's needs.
No reduction in injections
No reduction in central macular thickness
A couple letters of vision gain
No adverse events or side effects
Sounds more like a relatively harmless OTC product than a potent prescription drug
With deft marketing, it might be a winner.
Previously, he praised PVA management. Now he knocks them.
I have followed PVA a long time and management has brought the company this far with good moves in the Eagle Ford. Can you blame management for wanting to be rewarded for their good work?
A couple of letters of vision improvement -- but not much else to show for itself.
Squalamine now has a 20+ year history and it's just not potent enough to be very meaningful therapy.
If they can finesse the re-treatment criteria, they have a good complementary therapy that should attract a partner. Quality of life is all about vision gains and ability to drive and get around. FDA may look kindly on QOL benefits.
They are emphasizing quality of life benefits.
They say standards for retreatment were very strict -- moreso than in real-world settings.
They may go for a different endpoint in phase 3.
Number of Lucentis injections almost the same as the placebo group.
Some might call the data "mixed" -- some good and some not so good.
These results will not lower the cost of treatment -- maybe improve quality of life, though.
Think of PVA as EOG jr.
In this era of people who do a lot of talking and not much action, PVA is doubling down in the EF.
I do agree that they had better be correct.
If they are overplaying their hand, someone could step in now and make a takeover offer and steal the company.
I have been posting on this board since PVA was in the 4s.
I have also posted new well filings many times.
The posters who see some kind of conspiracy here do not know PVA.
The company has great drilling acreage and sees the tradeoff in common dilution as worth it to build production.
With all due respect, PVA is one of the more honest and responsive companies I have ever encountered